Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (ANNOUNCE-2)
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Your participation could last >12 months depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have completed all previous therapies more than 3 weeks before the first dose of study drug
Participant must be willing to provide tumor tissue
Participant must not be diagnosed with gastrointestinal stromal tumor (GIST) or Kaposi sarcoma
Participant must not have active central nervous system or brain metastasis at the start of the study
Participant must not have received prior treatment with gemcitabine or docetaxel (this includes participants previously enrolled in I5B-MC-JGDJ (NCT02451943)
Participant must not have planned elective surgery or will require surgery during study participation
Female participant must not be pregnant or breastfeeding
Participant must not have active fungal, bacterial, and/or known viral infection including HIV or viral (A, B, or C) hepatitis